Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05889195 · ClinicalTrials.gov registry record
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
A clinical trial of Urothelial Carcinoma, sponsored by Pacific Edge Limited.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 4
- Study locations
NCT05889195 is a study of Urothelial Carcinoma that is actively recruiting participants, run by Pacific Edge Limited. The registered enrollment target is 1,000 participants, above the 227-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (341% higher). The trial reports 4 study locations across 4 states.
The verdict
NCT05889195, a study of Urothelial Carcinoma, is actively recruiting participants, sponsored by Pacific Edge Limited.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 4
- Study locations
Study Summary
It is currently debated whether the use of invasive standard of care procedures, such as cystoscopy, a procedure which involves inserting a thin camera, called a cystoscope, into the bladder to look for signs of disease, is appropriate for patients with microscopic hematuria (blood in the urine that cannot be seen with the naked eye). This is because the risk of disease (bladder cancer - urothelial carcinoma) is relatively low in this population group, approximately 3%. Invasive procedures such as cystoscopy can cause anxiety and pain, in addition to other potential side effects. This has resulted in low admittance for cystoscopy among patients with hematuria (blood in urine) in urology clinics. Therefore, there is a need for a simpler, non-invasive test that can accurately detect the presence or absence of disease (urothelial carcinoma) in patients with microscopic hematuria. Cxbladder, a non-invasive, urine-based test, has the potential to fill this role.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Cxbladder urine test
Study Locations (4)
California
- Tri Valley Urology Medical Group - Murrieta
New York
- AccuMed Research Associates - Garden City
North Carolina
- Durham VA Health Care System - Durham
Texas
- The Urology Place - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2023-11-02 |
| Est. Completion | 2026-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05889195
The ClinicalTrials.gov registry entry for NCT05889195 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 227-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (341% higher). The listed sponsor is Pacific Edge Limited, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urothelial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Cxbladder urine test is the first listed.
NCT05889195 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05889195 about?
NCT05889195 is a clinical study titled "Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria". It is currently debated whether the use of invasive standard of care procedures, such as cystoscopy, a procedure which involves inserting a thin camera, called a cystoscope, into the bladder to look for signs of disease, is appropriate for patients with microscopic hematuria (blood in the urine that...
What is the current status of trial NCT05889195?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2023-11-02. Estimated completion is 2026-03-31.
What conditions does trial NCT05889195 study?
This clinical trial studies the following conditions: Urothelial Carcinoma.
What interventions are being tested in trial NCT05889195?
The interventions under investigation include: Cxbladder urine test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05889195?
This trial is sponsored by Pacific Edge Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05889195 being conducted?
This trial has 4 study locations across California, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
RECRUITING · Phase 3
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RECRUITING · Phase 2
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.